Awfis Space Solutions Clarification Regarding Recent Market Activity
Awfis Space Solutions has issued a formal statement addressing recent significant movements in its share price. The company confirmed it is…
Can Fin Homes Limited Q4 FY26 Results Reflect Strong Growth and Operational Excellence
Can Fin Homes Limited has reported a strong performance for Q4 FY26, with its total loan book reaching ₹42,209 crore, a 10% year-on-year…
United Breweries Limited Receives Favorable Tax Ruling in Bihar Litigation
United Breweries Limited has secured significant relief in a long-standing tax dispute in Bihar. The GST Commissioner (Appeals) has…
RBL Bank Announces Strong Financial Results for Q4 and FY26
RBL Bank has announced its financial performance for the quarter and year ended March 31, 2026. The bank recorded a net profit of ₹230 crore…
RBL Bank Reports Robust Q4 FY26 Performance with 234% Net Profit Growth
RBL Bank has announced strong financial results for the quarter and financial year ended March 31, 2026. The bank reported a significant 234%…
Manappuram Finance Limited Update Regarding Administrative Warning Letter
Manappuram Finance Limited has disclosed that its Chairman and Managing Director, Mr. V.P. Nandakumar, received an administrative warning…
Polycab India Incorporates Wholly Owned Subsidiary Polycon Infra Projects
Polycab India Limited has formally incorporated a new wholly owned subsidiary, Polycon Infra Projects Private Limited (PIPPL), as of April 24,…
Axis Bank Quarterly Profit Rises to ₹7,071 Crore Amid Strong Growth
Axis Bank reported a strong fiscal performance for the quarter ended March 31, 2026, with a Profit After Tax (PAT) of ₹7,071 crore, marking a…
Axis Bank Reports ₹7,071 Crore PAT for Q4 FY26, Driven by Strong Deposit Growth
Axis Bank announced its audited financial results for the quarter ended March 31, 2026, reporting a Profit After Tax (PAT) of ₹7,071 crore,…
Zydus Lifesciences Receives DCGI Approval for Phase III Trials of Zintrodiazine
Zydus Lifesciences has received approval from the DCGI to initiate two Phase III clinical trials for Zintrodiazine, a novel anti-malarial…